Mark N Stein | OMICS International
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mark N Stein

Rutgers Cancer Institute of New Jersey, 195 Little Albany Street New Brunswick, NJ

Phase II Study Evaluating the Effect of Concomitant Ramucirumab on the Pharmacokinetics of Docetaxel in Patients with Advanced Solid Tumors

Background: Ramucirumab is a human IgG1 monoclonal antibody that specifically targets the vascular endothelial growth factor receptor-2. The primary objective of this study was to investigate the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel. Methods: Patients with metastatic or locally advanced malignant solid tumors resis... Read More»

Mark N Stein, Laura Q M Chow, David C Smith, Dale R Shepard, Ding Wang, John Powderly, Archana Chaudhary, Yong Lin and Ling Gao

Research Article: Clin Pharmacol Biopharm 2016, 5:161

DOI: 10.4172/2167-065X.1000161

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article